Literature DB >> 31541547

Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.

Anton Chesnokov1,2, Mira C Patel1,3, Vasiliy P Mishin1, Juan A De La Cruz1,3, Lori Lollis1,3, Ha T Nguyen1,3, Vivien Dugan1, David E Wentworth1, Larisa V Gubareva1.   

Abstract

Susceptibility of influenza A viruses to baloxavir can be affected by changes at amino acid residue 38 in the polymerase acidic (PA) protein. Information on replicative fitness of PA-I38-substituted viruses remains sparse. We demonstrated that substitutions I38L/M/S/T not only had a differential effect on baloxavir susceptibility (9- to 116-fold) but also on in vitro replicative fitness. Although I38L conferred undiminished growth, other substitutions led to mild attenuation. In a ferret model, control viruses outcompeted those carrying I38M or I38T substitutions, although their advantage was limited. These findings offer insights into the attributes of baloxavir-resistant viruses needed for informed risk assessment. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  baloxavir acid; drug resistance; ferret; influenza; polymerase acidic protein

Mesh:

Substances:

Year:  2020        PMID: 31541547      PMCID: PMC8851376          DOI: 10.1093/infdis/jiz472

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.

Authors:  Henju Marjuki; Vasiliy P Mishin; Anton P Chesnokov; Juan A De La Cruz; Charles T Davis; Julie M Villanueva; Alicia M Fry; Larisa V Gubareva
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

2.  In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

Authors:  Takeshi Noshi; Mitsutaka Kitano; Keiichi Taniguchi; Atsuko Yamamoto; Shinya Omoto; Keiko Baba; Takashi Hashimoto; Kayo Ishida; Yukihiro Kushima; Kazunari Hattori; Makoto Kawai; Ryu Yoshida; Masanori Kobayashi; Tomokazu Yoshinaga; Akihiko Sato; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida; Takao Shishido; Akira Naito
Journal:  Antiviral Res       Date:  2018-10-11       Impact factor: 5.970

3.  A combination of HA and PA mutations enhances virulence in a mouse-adapted H6N6 influenza A virus.

Authors:  Likai Tan; Shuo Su; David K Smith; Shuyi He; Yun Zheng; Zhenwen Shao; Jun Ma; Huachen Zhu; Guihong Zhang
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

4.  Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease.

Authors:  Annelies Stevaert; Roberto Dallocchio; Alessandro Dessì; Nicolino Pala; Dominga Rogolino; Mario Sechi; Lieve Naesens
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

5.  Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.

Authors:  Frederick G Hayden; Norio Sugaya; Nobuo Hirotsu; Nelson Lee; Menno D de Jong; Aeron C Hurt; Tadashi Ishida; Hisakuni Sekino; Kota Yamada; Simon Portsmouth; Keiko Kawaguchi; Takao Shishido; Masatsugu Arai; Kenji Tsuchiya; Takeki Uehara; Akira Watanabe
Journal:  N Engl J Med       Date:  2018-09-06       Impact factor: 91.245

6.  Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler.

Authors:  Samuel S Shepard; Sarah Meno; Justin Bahl; Malania M Wilson; John Barnes; Elizabeth Neuhaus
Journal:  BMC Genomics       Date:  2016-09-05       Impact factor: 3.969

7.  Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.

Authors:  Shinya Omoto; Valentina Speranzini; Takashi Hashimoto; Takeshi Noshi; Hiroto Yamaguchi; Makoto Kawai; Keiko Kawaguchi; Takeki Uehara; Takao Shishido; Akira Naito; Stephen Cusack
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

8.  Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.

Authors:  Emi Takashita; Chiharu Kawakami; Rie Ogawa; Hiroko Morita; Seiichiro Fujisaki; Masayuki Shirakura; Hideka Miura; Kazuya Nakamura; Noriko Kishida; Tomoko Kuwahara; Akira Ota; Hayato Togashi; Ayako Saito; Keiko Mitamura; Takashi Abe; Masataka Ichikawa; Masahiko Yamazaki; Shinji Watanabe; Takato Odagiri
Journal:  Euro Surveill       Date:  2019-03

9.  Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.

Authors:  Larisa V Gubareva; Vasiliy P Mishin; Mira C Patel; Anton Chesnokov; Ha T Nguyen; Juan De La Cruz; Sarah Spencer; Angela P Campbell; Mallory Sinner; Heather Reid; Rebecca Garten; Jackie M Katz; Alicia M Fry; John Barnes; David E Wentworth
Journal:  Euro Surveill       Date:  2019-01

10.  Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors.

Authors:  Jeremy C Jones; Gyanendra Kumar; Subrata Barman; Isabel Najera; Stephen W White; Richard J Webby; Elena A Govorkova
Journal:  MBio       Date:  2018-04-24       Impact factor: 7.867

  10 in total
  14 in total

Review 1.  Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.

Authors:  Matt Shirley
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

2.  Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected with Respiratory Syncytial Virus.

Authors:  Danielle P Porter; Ying Guo; Jason Perry; David L Gossage; Timothy R Watkins; Jason W Chien; Robert Jordan
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

3.  Baloxavir Treatment Delays Influenza B Virus Transmission in Ferrets and Results in Limited Generation of Drug-Resistant Variants.

Authors:  Philippe Noriel Q Pascua; Jeremy C Jones; Bindumadhav M Marathe; Patrick Seiler; William V Caufield; Burgess B Freeman; Richard J Webby; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2021-08-23       Impact factor: 5.191

4.  Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.

Authors:  Brady T Hickerson; Simone E Adams; Subrata Barman; Lance Miller; Vladimir Y Lugovtsev; Richard J Webby; William L Ince; Raymond P Donnelly; Natalia A Ilyushina
Journal:  Antimicrob Agents Chemother       Date:  2022-03-09       Impact factor: 5.938

5.  Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.

Authors:  Jeremy C Jones; Philippe Noriel Q Pascua; Thomas P Fabrizio; Bindumadhav M Marathe; Patrick Seiler; Subrata Barman; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-26       Impact factor: 11.205

6.  Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition.

Authors:  Jeremy C Jones; Philippe N Q Pascua; Walter N Harrington; Richard J Webby; Elena A Govorkova
Journal:  J Antimicrob Chemother       Date:  2021-03-12       Impact factor: 5.790

7.  Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.

Authors:  Leo Y Lee; Jie Zhou; Paulina Koszalka; Rebecca Frise; Rubaiyea Farrukee; Keiko Baba; Shahjahan Miah; Takao Shishido; Monica Galiano; Takashi Hashimoto; Shinya Omoto; Takeki Uehara; Edin J Mifsud; Neil Collinson; Klaus Kuhlbusch; Barry Clinch; Steffen Wildum; Wendy S Barclay; Aeron C Hurt
Journal:  PLoS Pathog       Date:  2021-05-06       Impact factor: 6.823

Review 8.  Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.

Authors:  Michael G Ison; Frederick G Hayden; Alan J Hay; Larisa V Gubareva; Elena A Govorkova; Emi Takashita; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2021-08-04       Impact factor: 10.103

Review 9.  Next-generation direct-acting influenza therapeutics.

Authors:  Mart Toots; Richard K Plemper
Journal:  Transl Res       Date:  2020-02-04       Impact factor: 7.012

10.  A Quinolinone Compound Inhibiting the Oligomerization of Nucleoprotein of Influenza A Virus Prevents the Selection of Escape Mutants.

Authors:  Juliann Nzembi Makau; Ken Watanabe; Hiroki Otaki; Satoshi Mizuta; Takeshi Ishikawa; Yuji O Kamatari; Noriyuki Nishida
Journal:  Viruses       Date:  2020-03-19       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.